Cystic Fibrosis Clinical Trial
— G551DOfficial title:
Canadian Observation Trial in CF Patients Undergoing Treatment With Ivacaftor
Verified date | December 2017 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Specific aims:
1. To elucidate the biological mechanism that leads to pulmonary and nutritional
improvement in CF patients following treatment with ivacaftor using advanced techniques
to assess changes of the pulmonary and nutritional status
2. To examine the relation between the individual response to ivacaftor and the presence of
modifier genes associated with CF disease severity,
3. To assess altered CFTR function using new available in vivo tests,
4. To validate newly developed in vivo sweat tests with well established functional tests,
5. To establish correlation between the CFTR response to Vx-770 measured in a new ex vivo
method (organoids) and the actual clinical and/or functional response in individual
patients,
6. To examine response in other CF-specific features such as aqua wrinkling.
7. To examine if sleep/activity level changes.
8. To establish a biorepository to enable further investigations.
Status | Completed |
Enrollment | 18 |
Est. completion date | July 26, 2017 |
Est. primary completion date | July 26, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility |
Inclusion Criteria: - any patient being prescribed ivacaftor Exclusion Criteria: - only relates to specific tests |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tanja Gonska |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional in vivo Cystic fibrosis transmembrane conductor regulator (CFTR) tests: Nasal Potential difference (NPD) measurements | NPD is measured to assess CFTR function as difference in mV between post and pre-drug start | 7 study visits over a 2 year period | |
Primary | Functional in vivo test: Beta-adrenergic sweat secretion test | The beta-adrenergic sweat secretion test is measured as ratio of beta-adrenergic/cholinergic sweat secretion as difference between post and pre-drug start | 7 study visits over a 2 year period | |
Primary | Functional in vitro test: Rectal tissue biopsies to measure CFTR function in vitro using Ussing chamber studies and organoids | Rectal tissue specimen is being used to measure the response to ivcaftor of individual CF patients in vitro | one study visit | |
Primary | Functional in vitro test: Collect nasal brushes for CFTR to generate nasal cell cultures for the assessment of ivacaftor response and CFTR function | Nasal cultures are used to measure the response to ivcaftor in vitro as difference of the forskolin-induced response of CFTR to ivacaftor | 2 study visits in 6 months | |
Secondary | Measurement of aqua wrinkling | CF patients response to submerge in water for 5 min to develop a skin phenomenon known as aqua wrinkling is being measured subjectively pre and post-drug | 2 study visits in 3 months | |
Secondary | Measurement of exhaled fractionated nitrogen oxide (FeNo) | the fraction of the exhaled NO in % In the expiration of CF patients is being measured pre-and post-drug | 5 study visits in 1 year | |
Secondary | Measurements of the lung clearance index | Multiple breath wash-out technique is being used to measure the lung clearance index (no unit) pre and post-drug | 5 study visits in 1 year | |
Secondary | Measurements of the pancreas function using fecal elastase test | Fecal elastase in stool is determined in microg/g stool pre and post-drug | 4 study visits in 2 years | |
Secondary | Measurements of the pancreas function using serum trypsinogen | Serum trypsinogen is determined in nmol/L pre and post-drug | 4 study visits in 2 years | |
Secondary | Assessment of the nutritional status | Nutritional status is assessed using the BODPOD in kg fat or non-fat mass change or percentage fat or non-fat mass change pre and post-drug | 4 study visits in 2 years | |
Secondary | Measurements of the resting energy expenditure | The resting energy expenditure is measured using indirect calorimetry in kcal/d pre and post-post | 4 study visits in 2 years | |
Secondary | Assessment of pulmonary radiological changes using high resolution CT | Radiological pulmonary changes are being assessed using high resolution CT pre and post-drug (descriptive and Bhalla score) | 4 study visits in 2 years | |
Secondary | Assessment of glucose tolerance | Glucose tolerance is being assessed using the organ glucose tolerance test and glucose levels 2 hrs post in mmol/L will be compared pre and post-drug | 4 study visits in 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |